Cisplatin: A review of toxicities and therapeutic applications

Veterinary and Comparative Oncology

Volumn 6, Issue 1, 2008, Pages 1-18

  Barabas, K ^a   Milner, Rowan ^a   Lurie, D ^a   Adin, C ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

Chemotherapy; Cisplatin; Nephrotoxicity; Osteosarcoma

Indexed keywords

CANIS FAMILIARIS; EQUIDAE;

ANTINEOPLASTIC AGENT; CISPLATIN;

ANIMAL; ANIMAL DISEASE; CHEMICALLY INDUCED DISORDER; DOG; DOG DISEASE; HORSE; HORSE DISEASE; KIDNEY DISEASE; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOG DISEASES; DOGS; HORSE DISEASES; HORSES; KIDNEY DISEASES; NEOPLASMS;

EID: 61549087775     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2007.00142.x     Document Type: Review

References (154)

1. Rosenberg B, VanCamp L and Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-699.
2. Rosenberg B, VanCamp L, Trosko JE and Mansour VH. Platinum compounds: A new class of potent antitumour agents. Nature 1969; 222: 385-386.
3. Page R, Matus RE, Leifer CE and Loar A. Cisplatin, a new antineoplastic drug in veterinary medicine. Journal of the American Veterinary Medical Association 1985; 186: 288-290.
4. Reed E. Cisplatin, carboplatin, and oxaliplatin. In: Cancer Chemotherapy and Biotherapy Principles and Practice, 4 th edn., BA Chabner, and DL Longo, eds., Philadelphia, Lippincott Williams and Wilkins, 2006: 332-343.
5. Jacobs C, Kalman SM, Tretton M and Weiner MW Renal handling of cis-diamminedichloroplatinum(II). Cancer Treatment Reports 1980; 64: 1223-1226.
6. Choie DD, del Campo AA and Guarino AM. Subcellular localization of cis-dichlorodiammineplatinum(II) in rat kidney and liver. Toxicology and Applied Pharmacology 1980; 55: 245-252.
7. Litterst CL, Gram TE, Dedrick RL, LeRoy AF and Guarino AM. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Research 1976; 36: 2340-2344.
8. Campbell AB, Kalman SM and Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treatment Reports 1983; 67: 169-172.
9. Cvitkovic E, Spaulding J, Bethune V, Martin J and Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model. Cancer 1977; 39: 1357-1361.
10. Weiner IM. Transport of weak acids and bases. In: Handbook of Physiology. Renal Physiology, J Orloff, and RW Berliner, eds., Baltimore, Williams and Wilkins, 1973: 521-554.
11. Safirstein R, Miller P and Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney International 1984; 25: 753-758.
12. Litterst CL and Magin R. Alterations in plasma pharmacokinetics of cisplatin in tumor-bearing rats. Cancer Chemotherapy and Pharmacology 1988; 22: 1-4.
13. Rosenberg B. Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry. Cancer Treatment Reports 1979; 63: 1433-1438.
14. Litterst CL. Cisplatinum: A review, with special reference to cellular and molecular interactions. Agents and Actions 1984; 15: 520-524.
15. Harder HC and Rosenberg B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro. International Journal of Cancer 1970; 6: 207-216.
16. Howle JA and Gale GR. Cis-dichlorodiammineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochemistry and Pharmacology 1970; 19: 2757-2762.
17. Weiss RB and Poster DS. The renal toxicity of cancer chemotherapeutic agents. Cancer Treatment Reviews 1982; 9: 37-56.
18. Munchausen LL and Rahn RO. Biologic and chemical effects of cis-dichlorodiammineplatinum (II) (NSC-119875) on DNA. Cancer Chemotherapy Reports 1975; 59: 643-646.
19. Harder HC, Smith RG and LeRoy AF. Template primer inactivation by cis- and trans-dichlorodiammine platinum for human DNA polymerase alpha, beta, and Rauscher murine leukemia virus reverse transcriptase, as a mechanism of cytotoxicity. Cancer Research 1976; 36: 3821-3829.
20. Plooy AC, van DM and Lohman PH. Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Research 1984; 44: 2043-2051.
21. Masuda H, Tanaka T and Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochemical Biophysical Research Communications 1994; 203: 1175-1180.
22. Tanaka-Kagawa T, Kitahara J, Seko Y, Toyoda H, Imura N and Naganuma A. Reduced sensitivity of HeLa cells to cis-platinum by simultaneous overexpression of copper, zinc-superoxide dismutase and catalase. Biochemistry and Pharmacology 1999; 57: 545-548.
23. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC and Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 3070-3074.
24. Hosking LK, Whelan RD, Shellard SA, Bedford P and Hill BT. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines. Biochemistry and Pharmacology 1990; 40: 1833-1842.
25. Pattanaik A, Bachowski G, Laib J, Lemkuil D, Shaw CF, III, Petering DH, Hitchcock A and Saryan L. Properties of the reaction of cis-dichlorodiammineplatinum(II) with metallothionein. Journal of Biological Chemistry 1992; 267: 16121-16128.
26. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-1815.
27. Borst P, Evers R, Kool M and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute 2000; 92: 1295-1302.
28. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treatment Reviews 1998; 24: 331-344.
29. Villella J, Marchetti D, Odunsi K, Rodabaugh K, Driscoll DL and Lele S. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2004; 95: 539-545.
30. Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL and Howell SB. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clinical Cancer Research 1997; 3: 1763-1767.
31. Drummond JT, Anthoney A, Brown R and Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. Journal of Biological Chemistry 1996; 271: 19645-19648.
32. Nehme A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY and Christen RD. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. British Journal of Cancer 1999; 79: 1104-1110.
33. Lebwohl D and Canetta R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. European Journal of Cancer 1998; 34: 1522-1534.
34. Ries F and Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. American Journal of Kidney Diseases 1986; 8: 368-379.
35. Blachley JD and Hill JB. Renal and electrolyte disturbances associated with cisplatin. Annals of Internal Medicine 1981; 95: 628-632.
36. Madias NE and Harrington JT. Platinum nephrotoxicity. American Journal of Medicine 1978; 65: 307-314.
37. Dentino M, Luit FC, Yum MN, Williams SD and Einhom LH. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978; 41: 1274-1281.
38. Brillet G, Deray G, Jacquiaud C, Mignot L, Bunker D, Meillet D, Raymond F and Jacobs C. Long-term renal effect of cisplatin in man. American Journal of Nephrology 1994; 14: 81-84.
39. Dobyan DC, Levi J, Jacobs C, Kosek J and Werner MW. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. Journal of Pharmacology and Experimental Therapeutics 1980; 213: 551-556.
40. Schumer M, Colombel MQ, Sawczuk IS, Gobe G, Connor J, O'Toole KM, Olsson CA, Wise GJ and Buttyan R. Morphologic, biochemical, and molecular evidence of apoptosis during the reperfusion phase after brief periods of renal ischemia. American Journal of Pathology 1992; 140: 831-838.
41. Townsend DM, Deng M, Zhang L, Lapus MG and Hanigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. Journal of the American Society of Nephrology 2003; 14: 1-10.
42. Safirstein R, Winston J, Moel D, Dikman S and Guttenplan J. Cisplatin nephrotoxicity: Insights into mechanism. International Journal of Andrology 1987; 10: 325-346.
43. Fraval HN, Rawlings CJ and Roberts JJ. Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutation Research 1978; 51: 121-132.
44. Megyesi J, Andrade L, Vieira JM, Jr., Safirstein RL and Price PM. Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure. American Journal of Renal Physiology 2002; 283: F810-F816.
45. Megyesi J, Udvarhelyi N, Safirstein RL and Price PM. The p53-independent activation of transcription of p21 WAF1/CIP1/SDI1 after acute renal failure. American Journal of Physiology 1996; 271: F1211-F1216.
46. Megyesi J, Safirstein RL and Price PM. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. Journal of Clinical Investigation 1998; 101: 777-782.
47. Price PM, Safirstein RL and Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. American Journal of Renal Physiology 2004; 286: F378-F384.
48. Clarkson TW. The pharmacology of mercury compounds. Annual Review of Pharmacology 1972; 12: 375-406.
49. Levi J, Jacobs C, Kalman SM, McTigue M, Weiner MW. Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys. Journal of Pharmacology and Experimental Therapeutics 1980; 213: 545-550.
50. Lieberthal W, Triaca V and Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: Apoptosis vs. necrosis. American Journal of Physiology 1996; 270: F700-F708.
51. Kroemer G and Reed JC. Mitochondrial control of cell death. Nature Medicine 2000; 6: 513-519.
52. Brady HR, Kone BC, Stromski ME, Zeidel ML, Giebisch G and Gullans SR. Mitochondrial injury: An early event in cisplatin toxicity to renal proximal tubules. American Journal of Physiology 1990; 258: F1181-F1187.
53. Kruidering M, van de WB, de HE, Mulder GJ and Nagelkerke JF, Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. Journal of Pharmacology and Experimental Therapeutics 1997; 280: 638-649.
54. Davis CA, Nick HS and Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: Importance of superoxide. Journal of the American Society of Nephrology 2001; 12: 2683-2690.
55. Lau AH. Apoptosis induced by cisplatin nephrotoxic injury. Kidney International 1999; 56: 1295-1298.
56. Ye J, Wang S, Leonard SS, Sun Y, Butterworth L, Antonini J, Ding M, Rojanasakul Y, Vallyathan V, Castranova V and Shi X. Role of reactive oxygen species and p53 in chromium(VI)-induced apoptosis. Journal of Biological Chemistry 1999; 274: 34974-34980.
57. Cummings BS and Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. Journal of Pharmacology and Experimental Therapeutics 2002; 302: 8-17.
58. Xiao T, Choudhary S, Zhang W, Ansari NH and Salahudeen A. Possible involvement of oxidative stress in cisplatin-induced apoptosis in LLC-PK1 cells. Journal of Toxicology and Environmental Health A 2003; 66: 469-479.
59. Townsend DM and Hanigan MH. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. Journal of Pharmacology and Experimental Therapeutics 2002; 300: 142-148.
60. Hanigan MH, Lykissa ED, Townsend DM, Ou CN, Barrios R and Lieberman MW. Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. American Journal of Pathology 2001; 159: 1889-1894.
61. Hanigan MH, Gallagher BC, Taylor PT, Jr. and Large MK. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Research 1994; 54: 5925-5929.
62. Bemareggi A, Torti L, Faeino RM, Carini M, Depta G, Casetta B, Farrell N, Spadacini S, Ceserani R and Tognella S. Characterization of cisplatin-glutathione adducts by liquid chromatography-mass spectrometry. Evidence for their formation in vitro but not in vivo after concomitant administration of cisplatin and glutathione to rats and cancer patients. Journal of Chromatography B Biomedical Applications 1995; 669: 247-263.
63. Ishikawa T and Ii-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. Journal of Biological Chemistry 1993; 268: 20116-20125.
64. Gosland M, Lum B, Sehimmelpfennig J, Baker J and Doukas M. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 1996; 16: 16-39.
65. Hanigan MH, Gallagher BC, Townsend DM and Gabarra V. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis 1999; 20: 553-559.
66. Arany I and Safirstein RL. Cisplatin nephrotoxicity. Seminars in Nephrology 2003; 23: 460-464.
67. Safirstein R, Miller P, Dikman S, Lyman N and Shapiro C. Cisplatin nephrotoxicity in rats: Defect in papillary hypertonicity. American Journal of Physiology 1981; 241: F175-F185.
68. Chopra S, Kaufinan JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ, Flaraenbaum W and Trump BF. Cis-diamminedichlorplatinum-induced acute renal failure in the rat. Kidney International 1982; 21: 54-64.
69. Schor N, Ichikawa I, Rennke HG, Troy JL and Brenner BM. Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney International 1981; 19: 288-296.
70. Daugaard G and Abildgaard U. Cisplatin nephrotoxicity. A review. Cancer Chemotherapy and Pharmacology 1989; 25: 1-9.
71. Ogilvie GK, Krawiec DR, Gelberg HB, Twardock AR, Reschke RW and Richardson BC. Evaluation of a short-term saline diuresis protocol for the administration of cisplatin. American Journal of Veterinary Research 1988; 49: 1076-1078.
72. Ogilvie GK, Straw RC, Jameson VJ, Walters LM, Lafferty M, Powers BE, Henkel SE and Withrow SJ. Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol for the administration of cisplatin to dogs with naturally developing neoplasms. Journal of the American Veterinary Medical Association 1993; 202: 1845-1848.
73. Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, LeRoy A, Bachur NR and Wiernik PH. High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity. Cancer Treatment Reports 1981; 65: 73-78.
74. Pera MF Jr, Zook BC and Harder HC. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats. Cancer Research 1979; 39: 1269-1278.
75. Al-Sarraf M. Clinical trial of cis-platinum (NSC-119875): Hydration with and without mannitol in patients with previously treated advanced malignant melanoma. Proc Am Assoc Cancer Res and ASCO 1979; 20: 185.
76. Belt RJ and Taylor S. Randomized trial of hydration and mannitol in preventing cis -platinum induced nephrotoxicity. Proceedings of the American Association for Cancer Research and the American Society of Clinical Oncology 1979; 20: 388.
77. Litterst CL. Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Toxicology and Applied Pharmacology 1981; 61: 99-108.
78. Yuhas JM and Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treatment Reports 1980; 64: 57-64.
79. Weiner MW and Jacobs C. Mechanism of cisplatin nephrotoxicity. Federation Proceedings 1983; 42: 2974-2978.
80. Jones MM, Basinger MA and Holscher MA. Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. Fundamental and Applied Toxicology 1992; 18: 181-188.
81. Bodenner DL, Dedon PC, Keng PC and Borch RF. Effect of diethyldithiocarbamate on cis-diamminedichloro-platinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition. Cancer Research 1986; 46: 2745-2750.
82. Beny JM, Jacobs C, Sikic B, Halsey J and Borch RF. Modification of cisplatin toxicity with diethyldithiocarbamate. Journal of Clinical Oncology 1990; 8: 1585-1590.
83. Jacobs C, Kaubisch S, Halsey J, Lurn BL, Gosland M, Coleman CN and Sikic BT. The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 1991; 67: 1518-1524.
84. Wu YJ, Muldoon LL and Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. Journal of Pharmacology and Experimental Therapeutics 2005; 312: 424-431.
85. Howell SB, Pfeifle CE, Wung WE and Olshen RA. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Research 1983; 43: 1426-1431.
86. Dickey DT, Wu YJ, Muldoon LL and Neuwelt EA. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. Journal of Pharmacology and Experimental Therapeutics 2005; 314: 1052-1058.
87. Esposito M, Viale M, Vannozzi MO, Zicca A, Cadoni A, Merlo F and Gogioso L. Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedic-hloroplatinum(II). Toxicology and Applied Pharmacology 1996; 140: 370-377.
88. Viale M, Vannozzi MO, Pastrone I, Mariggio MA, Zicca A, Cadoni A, Cafaggi S, Tolino G, Lunardi G, Civalleri D, Lindup WE and Esposito M. Reduction of cisplatin nephrotoxicity by procainamide: Does the formation of a cisplatin-procainamide complex play a role? Journal of Pharmacology and Experimental Therapeutics 2000; 293: 829-836.
89. Vail DM, Elfarrn AA, Cooley AJ, Panciera DL, MacEwen EG and SoergeJ SA. Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model. Cancer Chemotherapy and Pharmacology 1993; 33: 25-30.
90. Thamm DH and Vail DM. Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats. American Journal of Veterinary Research 1998; 59: 286-289.
91. Fox LE, Toshach K, Calderwood-Mays M, Khokhar AR, Kubilis P, Perez-Soler R and MacEwen EG. Evaluation of toxicosis of liposome-encapsulated cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in clinically normal cats. American Journal of Veterinary Research 1999; 60: 257-263.
92. Marr AK, Kurzman ID and Vail DM. Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs. American Journal of Veterinary Research 2004; 65: 1474-1478.
93. McGinness JE, Proctor PH, Demopoulos HB, Hokanson JA and Kirkpatrick DS. Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase). Physiological Chemistry and Physics 1978; 10: 267-277.
94. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ and Motterlim R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. American Journal of Physiology Heart and Circulatory Physiology 2000; 278: H643-H651.
95. Foresti R, Green CJ and Motterlini R. Generation of bile pigments by haem oxygenase: A refined cellular strategy in response to stressful insults. Biochemical Society Symposium 2004; 71: 177-192.
96. Motterlini R, Gonzales A, Foresti R, Clark JE, Green CJ and Winslow RM. Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute hypertensive responses in vivo. Circulation Research 1998; 83: 568-577.
97. Sammut A, Foresti R, Clark JE, Exon DJ, Vesely MJ, Sarathchandra P, Green CJ and Motteriini R. Carbon monoxide is a major contributor to the regulation of vascular tone in aortas expressing high levels of haeme oxygenase-1. British Journal of Pharmacology 1998; 125: 1437-1444.
98. Otterbein LE, Bach FH, Alam J, Soares M, Tao LH, Wysk M, Davis RJ, Flavell RA and Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nature Medicine 2000; 6: 422-428.
99. Lavitrano M, Smolenski RT, Musumeci A, Maceherini M, Slominska E, Di FE, Bracco A, Mancini A, Stassi G, Patti M, Giovannoni R, Froio A, Simeone F, Fomi M, Bacci ML, D'Alise G, Cozzi E, Otterbein LE, Yacoub MH, Bach FH and Calise F. Carbon monoxide improves cardiac energetics and safeguards the heart during reperfusion after cardiopulmonary bypass in pigs. Federation of American Societies for Experimental Biology Journal 2004; 18: 1093-1095.
100. Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, Nick HS and Agarwal A. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. American Journal of Renal Physiology 2000; 278: F726-F736.
101. Tayem Y, Johnson TR, Mann BE, Green CJ and Motteriini R. Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule. American Journal of Physiology. Renal Physiology 2006; 290: F789-F794.
102. Barabas K, Milner R, Farese J, Adin C and Croker B. Hyperbilirubinemia protects against cisplatin nephrotoxicity. Proceeding of the Veterinary Cancer Society 2006; 36.
103. Schilsky RL and Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Annals of Internal Medicine 1979; 90: 929-931.
104. Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA and Dirks JH. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney International 1985; 28: 914-921.
105. Suh SM, Tashjian AH Jr, Matsuo N, Parkinson DK and Fraser D. Pathogenesis of hypocalcemia in primary hypomagnesemia: Normal end-organ responsiveness to parathyroid hormone, impaired parathyroid gland function. Journal of Clinical Investigation 1973; 52: 153-160.
106. Connor TB, Toskes P, MahafFey J, Martin LG, Williams JB and Walser M. Parathyroid function during chronic magnesium deficiency. The Johns Hopkins Medical Journal 1972; 131: 100-117.
107. Moore AS, Rand WM, Berg J, L'Heureux DA and Dennis RA. Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs. Journal of the American Veterinary Medical Association 1994; 205: 441-443.
108. Plumb D. In: Veterinary Drug Handbook, 5 th edn., D Plumb ed., Ames, Blackwell Publishing, 2005: 103, 162, 275, 520, 573.
109. Vail DM, Rodabaugh HS, Conder GA, Boucher JF and Mathur S. Efficacy of injectable maropitant (Cerenia TM) in a randomized clinical trial for prevention and treatment of cisplatin induced emesis in dogs presented as veterinary patients. Veterinary and Comparative Oncology 2007; 5: 38-46.
110. Ellerby RA, Davis HL Jr, Ansfield FJ and Ramirez G. Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875). Cancer 1974; 34: 1005-1010.
111. Green D. Pure tone air conduction threshold. In: Handbook of Clinical Audiology, Katz J, ed., Baltimore, Williams and Wilkins, 1972: 6.
112. Helson L, Okonkwo E, Anton L and Cvitkovic E. cis-Platinum ototoxicity. Clinical Toxicology 1978; 13: 469-478.
113. Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M and Meyer WH. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. Journal of Clinical Oncology 1989; 7: 754-760.
114. Pollera CF, Marolla P, Nardi M, Ameglio F, Cozzo L and Bevere F. Very high-dose cisplatin-induced ototoxicity: A preliminary report on early and long-term effects. Cancer Chemotherapy and Pharmacology 1988; 21: 61-64.
115. Pickrell JA, Oehme FW and Cash WC. Ototoxicity in dogs and cats. Seminars in Veterinary Medicine and Surgery (Small Animal) 1993; 8: 42-49.
116. Ozols RF and Young RC. High-dose cisplatin therapy in ovarian cancer. Seminars in Oncology 1985; 12(Suppl. 6): 21-30.
117. Sorensen JB, Andersen MK and Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. Journal of International Medicine 1995; 238: 97-110.
118. Shapiro W, Fossum TW, Kitchell BE, Couto CG and Theilen GH. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. Journal of the American Veterinary Medical Association 1988; 192: 507-511.
119. Rraegel SA, Madewell BR, Simonson E and Gregory CR. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). Journal of the American Veterinary Medical Association 1991; 199: 1057-1059.
120. Straw RC, Withrow SJ, Richter SL, Powers BE, Klein MK, Postorino NC, LaRue SM, Ogilvie GK, Vail DM and Morrison WB. Amputation and cisplatin for treatment of canine osteosarcoma. Journal of Veterinary Internal Medicine 1991; 5: 205-210.
121. Thompson JP and Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). Journal of the American Veterinary Medical Association 1992; 200: 531-533.
122. Berg J, Weinstein MJ, Schelling SH and Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). Journal of the American Veterinary Medical Association 1992; 200: 2005-2008.
123. Mauldin GN, Matus RE, Withrow SJ and Patnaik AK. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. Journal of Veterinary Internal Medicine 1988; 2: 177-180.
124. Chun R, Garrett LD, Henry C, Wall M, Smith A and Azene NM. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. Journal of the American Animal Hospital Association 2005; 41: 382-387.
125. Berg J, Gebhardt MC and Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997; 79: 1343-1350.
126. Knapp DW, Richardson RC, Bonney PL and Hahn K. Cisplatin therapy in 41 dogs with malignant tumors. Journal of Veterinary Internal Medicine 1988; 2: 41-46.
127. Vail DM, Kurzman ID, Glawe PC, O'Brien MG, Chun R, Garrett LD, Obradovich JE, Fred RM, III, Khanna C, Colbem GT and Working PK. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: A randomized multicenter clinical trial. Cancer Chemotherapy and Pharmacology 2002; 50: 131-136.
128. Withrow SJ, Liptak JM, Straw RC, Demell WS, Jameson VJ, Powers BE, Johnson JL, Brekke JH and Douple EB. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Annals of Surgical Oncology 2004; 11: 705-713.
129. Hahn KA, Richardson RC, Blevins WE, Lenz SD and Knapp DW. Intramedullary cisplatin chemotherapy: Experience in four dogs with osteosarcoma. Journal of Small Animal Practice 1996; 37: 187-192.
130. Shapiro W, Kitchell BE, Fossum TW, Couto CG and Theilen G. Cisplatin for treatment of transitional cell and squamous cell carcinomas in dogs. Journal of the American Veterinary Medical Association 1988; 193: 1530-1533.
131. Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): A review of experimental and clinical data. International Journal of Radiation Oncology Biology Physics 1987; 13: 403-426.
132. Begg AC. Cisplatin and radiation: Interaction probabilities and therapeutic possibilities. International Journal of Radiation Oncology Biology Physics 1990; 19: 1183-1189.
133. Coughlin CT and Richmond RC. Biologic and clinical developments of cisplatin combined with radiation: Concepts, utility, projections for new trials, and the emergence of carboplatin. Seminars in Oncology 1989; 16(Suppl. 6): 31-43.
134. Douple EB. Platinum-radiation interactions. National Cancer Institute Monographs 1988; 6: 315-319.
135. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Sehuller DE and Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. Journal of Clinical Oncology 1998; 16: 1310-1317.
136. Nadeau ME, Kitchell BE, Rooks RL and LaRue SM. Cobalt radiation with or without low-dose cisplatin for treatment of canine naso-sinus carcinomas. Veterinary Radiology & Ultrasound 2004; 45: 362-367.
137. Lana SE, Dernell WS, Lafferty MH, Withrow SJ and LaRue SM. Use of radiation and a slow-release cisplatin formulation for treatment of canine nasal tumors. Veterinary Radiology & Ultrasound 2004; 45: 577-581.
138. Freeman KP, Hahn KA, Harris FD and King GK. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). Journal of Veterinary Internal Medicine 2003; 17: 96-101.
139. Kitchell BE, Brown DM, Luck EE, Woods LL, Orenberg EK and Bloch DA. Intralesional implant for treatment of primary oral malignant melanoma in dogs. Journal of the American Veterinary Medical Association 1994; 204: 229-236.
140. Moore AS, Kirk C and Cardona A. Intracavitary cisplatin chemotherapy experience with six dogs. Journal of Veterinary Internal Medicine 1991; 5: 227-231.
141. Myers CE and Collins JM. Pharmacology of intraperitoneal chemotherapy. Cancer Investigation 1983; 1: 395-407.
142. Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treatment Review 1986; 13: 219-242.
143. Charney SC, Bergman PJ, McKnight JA, Farrelly J, Novosad CA, Leibman NF and Camps-palau MA. Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis, and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997-2002). Veterinary and Comparative Oncology 2005; 3: 171-181.
144. Knapp DW, Richardson RC, DeNicola DB, Long GG and Blevins WE. Cisplatin toxicity in cats. Journal of Veterinary Internal Medicine 1987; 1: 29-35.
145. Shapiro W. Cisplatin chemotherapy. In: Current Veterinary Therapy X, Kirk RW, ed., Philadelphia, WB Saunders Co, 1989: 497-501.
146. Fox LE, Rosenthal RC, King RR, Levine PB, Vail DM, Helfand SC, MacEwen EG, Perez-Soler R, Calderwood-Mays M and Kurzman ID. Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. American Journal of Veterinary Research 2000; 61: 791-795.
147. Theon AP, Pascoe JR, Carlson GP and Krag DN. Intratumoral chemotherapy with cisplatin in oily emulsion in horses. Journal of the American Veterinary Medical Association 1993; 202: 261-267.
148. Theon AP, Pascoe JR, Madigan JE, Carlson G and Metzger L. Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses. American Journal of Veterinary Research 1997; 58: 431-436.
149. Theon AP, Pascoe JR and Meagher DM. Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumors in equidae. Journal of the American Veterinary Medical Association 1994; 205: 1170-1176.
150. Theon AP, Pascoe JR, Galuppo LD, Fisher PE, Griffey SM and Madigan JE. Comparison of perioperative versus postoperative intratumoral administration of cisplatin for treatment of cutaneous sarcoids and squamous cell carcinomas in horses. Journal of the American Veterinary Medical Association 1999; 215: 1655-1660.
151. Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, Hale A, Kruth SA, Klein MK, Klausner J, Norris AM, McCaw D, Straw RC and Withrow SJ. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991-1993). Journal of Veterinary Internal Medicine 1996; 10: 76-81.
152. Kent MS, Strom A, London CA and Seguin B. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. Journal of Veterinary Internal Medicine 2004; 18: 540-544.
153. Chun R, Knapp DW, Widmer WR, DeNicola DB, Glickman NW, Kuczek T, Degortari A and Han CM. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine 1997; 11: 279-283.
154. Kirpensteijn J, Teske E, Kik M, Klenner T and Rutteman GR. Lobaplatin as